Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
5.01
+0.28 (5.92%)
At close: Jan 17, 2025, 4:00 PM
4.915
-0.100 (-1.90%)
Pre-market: Jan 21, 2025, 8:00 AM EST
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 28 employees as of December 31, 2023. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$2,029,750
Market Cap
321.93M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CRVS News
- 8 days ago - Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - GlobeNewsWire
- 13 days ago - Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting - Seeking Alpha
- 4 weeks ago - Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? - Benzinga
- 4 weeks ago - Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 4 weeks ago - Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - GlobeNewsWire
- 4 weeks ago - Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - GlobeNewsWire
- 6 weeks ago - Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity - GlobeNewsWire